

**Bafna Pharmaceuticals Limited**

CIN: L24294TN1995PLC030698

Corporate Office and Registered Office: Bafna Towers, New No. 68, Old No 299, Tambu Chetty Street, Chennai-600001 (Tamil Nadu)

Email : cs@bafnapharma.com Web : www.bafnapharma.com

(₹ in Lakhs)

**Statement of Unaudited Financial Results for the Quarter Ended 30th June, 2022**

Particulars	Quarter Ended			Year Ended
	30-Jun-22	31-Mar-22	30-Jun-21	31-Mar-22
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
1 Revenue from Operations	1,692.68	1,498.24	2,125.86	8,514.03
Other Income	130.14	126.84	17.00	210.21
<b>Total Income (Net)</b>	<b>1,822.82</b>	<b>1,625.08</b>	<b>2,142.86</b>	<b>8,724.24</b>
<b>2 Expenses</b>				
Cost of Material Consumed	1,059.49	1,072.33	1,361.65	5,305.99
Change in Inventories of finished goods, Stock-in-Trade and Work in Progress	(14.43)	(107.52)	(53.71)	(177.40)
Employee Benefits Expenses	350.19	371.06	325.99	1,450.39
Finance Costs	31.25	16.76	10.61	79.38
Depreciation and Amortization Expenses	128.64	140.13	146.09	549.33
Other Expenses	131.47	214.69	143.54	785.79
<b>Total Expenses</b>	<b>1,686.61</b>	<b>1,707.45</b>	<b>1,934.17</b>	<b>7,993.48</b>
<b>3 Profit from ordinary Activities before Exceptional Items &amp; tax (1-2)</b>	<b>136.21</b>	<b>(82.37)</b>	<b>208.69</b>	<b>730.76</b>
4 Exceptional Items	-	19.12	-	215.65
<b>5 Profit from ordinary Activities before tax (3-4)</b>	<b>136.21</b>	<b>(101.49)</b>	<b>208.69</b>	<b>515.11</b>
6 Tax Expense - Current Taxes	-	-	-	-
- MAT Credit	-	-	-	-
-For Deferred Taxes	-	-	-	-
<b>7 Net Profit from ordinary activities after tax (5-6)</b>	<b>136.21</b>	<b>(101.49)</b>	<b>208.69</b>	<b>515.11</b>
8 Other Comprehensive Income	(0.60)	10.66	-	(2.40)
<b>9 Total Comprehensive Income, Net of Income Tax (7+8)</b>	<b>135.61</b>	<b>(90.83)</b>	<b>208.69</b>	<b>512.71</b>
10 Paid Equity Share Capital (Face Value of ₹ 10 Each)	2,365.63	2,365.63	2,365.63	2,365.63
11 Other Equity as per the Balance Sheet				3,992.40
12 Earning Per Share				
Basic Earning Per Share	0.57	(0.38)	0.88	2.17
Diluted Earning Per Share	0.57	(0.38)	0.88	2.17

**Notes:**

1. The above unaudited financial results for the quarter ended June 30, 2022, have been reviewed by the Audit Committee on August 10, 2022 and thereafter approved by the Board of Directors of the Company at their respective meetings held on August 11, 2022. The Statutory Auditor has conducted a "Limited Review" of these financial results in terms of Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

2. The figures of the quarter ended March 31, 2022 are the balancing figures between audited figures in respect of the full financial year ended March 31, 2022 and the unaudited published year to date figures up to December 31, 2021.

3. The above results have been prepared in accordance with Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

4. Company's business relates to the manufacturing of pharmaceutical formations, which in context of Indian Accounting Standards 108 (Ind AS 108) as notified under Section 133 of the Companies Act, 2013 is considered as the only segment.

5. Previous period figures have been regrouped, reclassified and restated to conform to those of the current period.

6. Being the First Quarter of the year, Figures of the Quarter ended 30th June 2022 and Year to date for this Quarter are same hence not mentioned separately.

For Bafna Pharmaceuticals Limited

Place: Chennai  
Date: 11th August 2022



*S. Hemalatha*  
S. Hemalatha  
Executive Director  
(DIN: 02714329)